Eye Stroke and Weight Loss Injections: What You Demand to Know
Recent reports have highlighted a rare but serious potential side effect associated with weight-loss injections: a condition informally termed “eye stroke.” While not a formal medical diagnosis, this term describes sudden vision loss caused by reduced blood flow to the optic nerve. Here’s a comprehensive look at what this means, the connection to medications like Wegovy and Ozempic, and what you should be aware of.
What is an “Eye Stroke”?
An “eye stroke” is not a stroke in the traditional sense, which affects blood flow to the brain and can cause limb weakness or speech difficulties. Instead, it refers to non-arteritic anterior ischaemic optic neuropathy (NAION), a condition where blood flow to the optic nerve is disrupted, leading to sudden, painless vision loss. This vision loss can be partial or complete, and can occur in one or both eyes.
The Link to Weight Loss Medications
The connection between NAION and weight-loss treatments gained attention following a study analyzing over 30 million side effects reported to the US Food and Drug Administration. The study found that 31,774 side effects involved semaglutide, the active ingredient in several popular weight-loss drugs, including Wegovy and Ozempic.
Wegovy vs. Ozempic: A Difference in Risk
The research indicated a significantly higher risk associated with Wegovy compared to Ozempic. The study suggested the risk of eye stroke from Wegovy was almost five times greater than from Ozempic, despite Wegovy being linked to fewer overall reported side effects.
How Semaglutide Might Affect Blood Flow
Semaglutide is a synthetic version of the naturally occurring hormone GLP-1, which regulates blood sugar by stimulating insulin production, reducing glucagon release, and slowing digestion. The higher doses used in Wegovy, administered by injection, may lead to fluctuations in blood pressure. Reduced blood pressure can disrupt blood flow, particularly to the retina, which has tiny, delicate blood vessels. The rapid weight loss induced by Wegovy may also play a role, as the body strives to maintain hormonal balance.
Who is at Higher Risk?
The study revealed a notable disparity in risk based on sex. Men taking these weight-loss treatments appeared to face three times the risk of vision loss compared to women. Still, the reasons for this difference are not yet fully understood and require further investigation. The study did not provide enough detail about the differences between male and female participants.
What You Should Do
While the risk of NAION remains rare, it’s crucial to be aware of the potential side effect. If you are taking semaglutide and experience sudden vision loss, seek immediate medical attention. Novo Nordisk, the manufacturer of Wegovy and Ozempic, has updated patient leaflets to include information about NAION and maintains that the benefit-risk profile of semaglutide remains favorable.
Looking Ahead
More research is needed to establish safe dosage levels and identify factors that may increase vulnerability to NAION. Properly designed clinical trials are essential to assess the level of risk associated with semaglutide and similar medications, especially as their use expands to a wider range of conditions and younger patients.